Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments

Daisuke Akazawa(National Institute of Infectious Diseases), Koichi Watashi(Tokyo University of Science), Michiyo Kataoka(National Institute of Infectious Diseases), Yoshimasa Takahashi(Hokkaido Pharmaceutical University), Hirofumi Ohashi(Aichi Medical University), Junki Mifune(National Institute of Infectious Diseases), Yong Dam Jeong(Pusan National University), Shinjiro Ojima(National Institute of Infectious Diseases), Tomoki Yoshikawa(Okayama University), Tadaki Suzuki(National Institute of Infectious Diseases), Takayuki Hishiki(National Institute of Infectious Diseases), Hideki Ebihara(National Institute of Infectious Diseases), Ken Maeda(National Institute of Infectious Diseases), Shingo Iwami(Kyushu University), Aa Haeruman Azam(Tokyo Institute of Technology), Kwang Su Kim(Nagoya University), Kana Tsuchimoto(National Institute of Infectious Diseases), Kaho Shionoya(Tokyo University of Science), Masayuki Shimojima(The University of Tokyo), Takeshi Morita(National Institute of Infectious Diseases), Shoya Iwanami(Nagoya University), Eun‐Sil Park(University of Kentucky), Hyeongki Park(Nagoya University), Shogo Nakajima(National Institute of Infectious Diseases), Kotaro Kiga(Jichi Medical University)
bioRxiv (Cold Spring Harbor Laboratory)
August 2, 2022
Cited by 15


Related Papers